NMNH vs NR: What the Different Evidence Bases Can and Cannot Show

NMNH and NR cannot be ranked by placing a mouse result beside a human trial result as if the columns were equivalent. NMNH, reduced nicotinamide mononucleotide, has preclinical research and a preliminary human report. NR, nicotinamide riboside, has multiple published human studies. Different evidence levels answer different questions.

The studies cited here do not provide a direct human head-to-head comparison of NMNH with NR. “Better,” “faster,” and percentage-superiority claims are therefore unsupported for human product comparison.

Put evidence levels in separate rows

An empty cell is a finding. It should say “not established” rather than borrowing a result from a related molecule.

What the foundational NMNH paper tested

A 2021 paper introduced a synthesis method for NMNH and evaluated it in mammalian cells and mice. It reported that NMNH raised NAD+ more rapidly and to a greater extent than NMN or NR in those experimental systems, described a different metabolic pathway, and studied hypoxia-reoxygenation injury in renal tubular cells. Read the paper.

The comparison belongs to cells and mice, with the materials, routes, and measurements used by the investigators. It does not establish a human absorption multiple, a 15-minute consumer outcome, 24-hour benefit, kidney treatment, or a human dose. Animal milligrams per kilogram should not be converted by simple body-weight multiplication.

The paper included authors affiliated with Nestlé Research, which is relevant context when evaluating commercial translation. Conflict information should be recorded without dismissing the methods or treating the study as independent replication.

What the current NMNH registration means

ClinicalTrials.gov lists a randomized, double-blind, placebo-controlled study of a branded NMNH material in adults aged 40 to 65, with several capsule doses over 90 days and planned outcomes including blood NAD+, physical performance, quality of life, BMI, safety, and tolerability. Read the registration.

The registry marks the study completed but does not post results. An August 2026 preprint reports an 80-participant, 90-day trial of NMNH calcium salt. It is preliminary and not peer-reviewed; it does not test Granver’s finished blend or compare NMNH directly with NR. Study completion, a preprint, and peer-reviewed confirmation are distinct evidence stages.

What published NR trials show

A randomized crossover trial in 24 healthy middle-aged and older adults evaluated chronic NR supplementation and reported that it was well tolerated and increased blood NAD-related measures. Read the trial. The study was small, and biomarker changes were more clearly established than broad functional benefits.

An eight-week randomized trial tested 100, 300, and 1,000 mg per day of a specific NR chloride material in adults with overweight and reported dose-related increases in whole-blood NAD+. Read the trial. Industry relationships and the exact branded material are part of interpreting the result.

These studies establish published human experience for NR under specific protocols. They do not prove that NR extends lifespan, reverses aging, or is superior or inferior to NMNH. They also do not establish what an undisclosed NMNH amount will do.

The NAD+ cellular-energy guide explains why blood biomarkers and clinical outcomes should remain separate.

Chemistry does not provide a dose conversion

NMNH, NR, and NMN have different molecular weights, redox states, stability concerns, transport and metabolic paths. Equal milligrams are not necessarily equal molecule counts, exposure, or effect. Even molar equivalence would not prove biological equivalence.

Do not create a conversion factor from a mouse curve, cell-culture concentration, or marketing diagram. A faster rise in one tissue under a preclinical protocol does not predict a faster feeling or a better health outcome in a person.

The NMNH versus NMN overview and ingredient-quality checklist provide adjacent comparisons without filling the NMNH-versus-NR human evidence gap.

What NAD+ Supreme discloses

The current NAD+ Supreme serving is two capsules. A 220 mg Proprietary Rejuvenation Complex lists proprietary NMNH, L-ergothioneine, Goldgin ginseng, and PowerGrape. A separate 180 mg complex lists other ingredients. NR is not listed.

The 220 mg total belongs to four ingredients and cannot be called an NMNH dose. Ingredient order does not reveal the numerical amount. The formula is also not the single NMNH material or single NR material used in the cited studies.

Review the current NAD+ Supreme product page and the healthy-aging supplement guide before interpreting broader claims.

A research-matching worksheet

Record the exact precursor, chemical form, individual amount, route, formulation, comparator, sample, assay, participants, duration, endpoint, adverse events, funding, conflicts, registration, and publication status. Then mark each field as matching, different, or unknown.

This process may show that NR has more published human evidence while leaving the choice between NMNH and NR unresolved. Evidence volume alone does not answer suitability, and preclinical magnitude does not overcome missing human comparison data.

Granver's claims-review framework provides the same discipline for finished formulas.

Do not compare study percentages directly

A percentage change depends on the baseline, specimen, assay, sampling time, dose, and statistical analysis. If an NMNH mouse experiment reports a multiple in one tissue and an NR human trial reports a percentage in whole blood, the values do not share a denominator or biological context.

Absolute concentrations can also be noncomparable when laboratories use different extraction, internal standards, and normalization. Copying the larger number into a product table would reward methodological difference rather than better evidence.

Safety evidence is unequal too

NR's published human trials provide adverse-event and laboratory data for defined materials, amounts, and durations. That history does not guarantee safety for every person, higher amount, longer period, or multi-ingredient product. Preliminary NMNH human findings require peer review, replication, and longer follow-up before they can answer broader safety questions.

Absence of published harm is not proof of safety. Record participant counts, withdrawals, adverse events, laboratory monitoring, excluded populations, and duration. Pregnancy, breastfeeding, cancer treatment, surgery, kidney or liver disease, and prescription medicine use require individualized review.

Registration and publication can diverge

When following the NMNH trial, compare the registry's original and updated outcomes, enrollment, dates, sponsor, statistical plan, and posted results. A later publication should be matched by registration number and methods. Selective publication can occur when only favorable endpoints appear in marketing.

An abstract, press release, or conference poster may be informative but usually provides less detail than a full report. Do not convert preliminary language into “clinically proven.” Before relying on a reported result, check the material, dose, protocol, analysis, harms, and conflicts in the full report.

Finished-product quality remains separate

Even a strong single-ingredient trial would not validate a proprietary blend automatically. A finished product needs identity, assay, contaminants, uniformity, dissolution or release information when relevant, and stability through shelf life. The study material and consumer product must be linked by documentation.

For NAD+ Supreme, request the individual NMNH amount and finished-product assay. Without them, neither the mouse study nor the registered human doses can be matched to the two-capsule serving.

For the latest status and posted results, check the linked trial registry. Registration alone does not establish a benefit.

FAQs

Your next step

Use the evidence-level table before comparing products, and keep the NMNH amount on the current NAD+ Supreme label marked unknown until a finished-product specification discloses it.

Educational information only. Granver products are dietary supplements and are not intended to diagnose, treat, cure, or prevent disease. This article does not replace individualized medical care.